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Design, synthesis and potential anti-proliferative activity of 
some novel 4-aminoquinoline derivatives
Novel nineteen compounds based on a 4-aminoquinoline 
scaffold were designed and synthesized as potential anti-
proliferative agents. The new compounds were N-substi-
tuted at the 4-position by aryl or heteroaryl (1-9), quinolin-
3-yl (10), 2-methylquinolin-3-yl (11), thiazol-2-yl (12), and 
dapsone moieties (13, 14 and 18). Bis-compounds 15, 16 and 
19 were also synthesized to assess their biological activity. 
All the newly synthesized comounds were tested for in vitro 
antipro liferative activity against the MCF-7 breast cancer cell 
line. Seventeen of the novel compounds showed higher ac ti-
vi ty than the reference drug doxorubicin. The cor res pond ing 
7-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-
amine 1, N-(7-(trifluoromethyl)quinolin-4-yl)quino lin-3-
amine (10), 2-methyl-N-(7-trifluorome-thyl)quinolin-4-yl)
quinolin-3-amine (11) and N-(4-(4-aminophenylsulfonyl)
phenyl)-7-chloroquinolin-4-amine (13) were almost twice 
to thrice as potent as doxorubicin. Biological screening of 
the tested compounds could offer an encouraging frame-
work in this field that may lead to the discovery of potent 
anticancer agents.
Keywords: 4-aminoquinolines, bis-compounds, dapsone, 
antiproliferative activity
Nitrogen containing heterocycles are indispensable structural units in medicinal 
chemistry. Among various heterocyclic compounds, quinolines (1, 2) occur predominan-
tely in nature because of their stability and ease of generation. They exhibit a multitude of 
biological utilities, such as anticancer (3), antioxidant (4), anti-proliferative (5), and anti-
inflammatory properties (6). Since the discovery of the chemo-sensitisation of the multi-
drug resistance (MDR) cancer cell lines by chloroquine  I (7)  and primaquine II (8) in the 
1980s (Fig. 1), little work has been done to exploit these antimalarial agents as effective 
agents in the management of cancer. Also, several adamantane, morpholine, pyrimidine, 
triazine, quinoline and benzothiazole derivatives were associated with anticancer (9) and 
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were reported to possess significant anticancer activity (11). In view of the above mention-
ed findings and as a part of our research efforts to explore  novel anti-proliferative hetero-
cyclic compounds (12–18), we have synthesized a new series of 4-aminoquinoline deriva-
tives bearing a number of the biologically active moieties mentioned above, as analogues 
to compounds I and II. Anti-proliferative activity of the synthesized compounds was 
evaluated against the human breast cancer cell line MCF-7.
EXPERIMENTAL
Melting points (uncorrected) were determined in open capillaries on a Gallen Kemp 
melting point apparatus (Sanyo Gallen Kemp, UK). Precoated silica gel plates (Kieselgel 
0.25 mm, 60 F254, Merck, Germany) were used for thin layer chromatography. A develop-
ing solvent system of chloroform/methanol (8:2) was used and the spots were detected by 
ultraviolet light. IR spectra (KBr disc) were recorded using an FT-IR spectrophotometer 
(Perkin Elmer, USA). 1H NMR spectra were scanned on a NMR spectrophotometer (Bruker 
AXS Inc., Switzerland) operating at 500 MHz for 1H and 125.76 MHz for 13C. Chemical 
shifts are expressed in d-values (ppm) relative to TMS as an internal standard, using 
DMSO-d6 as a solvent. Elemental analyses were done on a model 2400 CHNSO analyzer 
(Perkin Elmer, USA). All the values were within ± 0.4 % of theoretical values. 
All reagents used were of AR grade. The starting materials 4,7-dichloroquinoline and 
4-chloro-7-trifluoromethylquinoline were purchased from Sigma (USA) and were directly 
used for the preparation of target compounds.
Syntheses
Quinoline derivatives 7-(trifluoromethyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine (1), 
N-(3-methylbicyclo[3.3.1]nonan-3-yl)-7-(trifluoromethyl)quinolin-4-amine (2), 7-chloro-N-(4-
morpholinophenyl)quinolin-4-amine (3), N-(4-morpholinophenyl)-7-(trifluoromethyl)quinolin-4-
amine (4), 5-(7-(trifluoromethyl)quinolin-4-ylamino)pyrimidin-2,4-(1H,3H)-dione (5), 1,3-dimeth-
yl-6-(7-(trifluoromethyl)quinolin-4-ylamino)pyrimidin-2,4-(1H,3H)-dione (6), N-(benzo[d] [1,3] 
dio xol-5-ylmethyl)-7-chloroquinolin-4-amine (7), N-(benzo[d] [1,3] dioxol-5-ylmethyl)-7-(tri flu-
oro methyl) quinolin-4-amine (8), N-(5,6-dimethyl-1,2,4-triazin-3-yl)-7-(trifuoloromethyl) quino-
lin-4-amine (9), N-(7-(trifluoromethyl)quinolin-4-yl)quinolin-3-amine (10), 2-methyl-N-(7-triflu-
oromethyl) quinolin-4-yl)quinolin-3-amine (11), 6-methoxy-N-(7-(trifluoromethyl) quinolin-4-yl) 
benzo[d]thiazol-2-amine (12). General procedure – A mixture of 4,7-dichloroquinoline or 
4-chloro-7-trifluoromethylquinoline (0.01 mol) and the appropriate amine (0.01 mol) in dry 
Fig. 1. Structures of chloroquine I and primaquine II.
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1 C19H17F3N2O3 (378.35) 213.3 88 60.32/60.64 4.53/4.19 7.40/7.76
2 C20H21F3N2 (346.41) 220.2 76 68.95/68.68 6.65/6.39 8.04/8.31
3 C19H18ClN3O (339.82) 326.6 81 67.15/67.47 5.34/5.14 12.37/12.66 
4 C20H18F3N3O (373.37) 286.0 77 64.34/64.63 4.86/4.58 11.25/11.59
5 C14H9F3N4O2 (322.24) > 350 69 52.18/52.50 2.82/2.60 17.39/17.14
6 C16H13F3N4O2 (350.30)) 242.6 73 54.86/54.59 3.74/3.48 15.99/15.66
7 C17H13ClN2O2 (312.75) > 350 89 65.29/65.56 4.19/4.49 8.96/8.61
8 C18H13F3N2O2 (346.30) > 350 82 62.43/62.12 3.78/3.48 8.09/8.31
9 C15H12F3N5 (319.28) > 350 59 56.43/56.71 3.79/3.58 21.93/21.66
10 C19H12F3N3 (339.31) 251.2 61 67.25/67.55 3.56/3.19 12.38/12.65
11 C20H14F3N3 (353.34) 68.8 59 67.98/67.69 3.99/3.70 11.89/11.62
12 C19H14F3N3OS (389.08) 208.0 71 58.60/58.35 3.62/3.29 10.79/10.48
13 C12H16ClN3O2S (409.89) 136.8 65 61.53/61.18 3.93/3.70 10.25/10.56
14 C22H16F3N3O2S (443.44) 118.1 71 59.59/59.20 3.64/3.28 9.48/9.76
15 C30H20Cl2N4O2S (571.48) 340.1 55 63.05/63.29 3.53/3.19 9.80/9.51
16 C32H20F6N4O2S (638.58) 148.6 61 60.19/60.50 3.16/3.48 8.77/8.45
17 C10H5ClN2S (220.68) 114.7 94 54.43/54.67 2.28/2.60 12.69/12.44
18 C22H17ClN4O2S2 (468.98) 159.6 59 56.34/56.61 3.65/3.26 11.95/11.69
19 C32H22Cl2N6O2S3 (689.66) 258.9 55 55.73/55.48 3.22/3.50 12.15/12.49
DMF (20 mL) was refluxed for 18 h. The reaction mixture was poured onto ice/water and 
the obtained solid was recrystallized from dioxane to give 1–12, respectively (Table I).
N-(4-(4-aminophenylsulfonyl) phenyl)-7-chloroquinolin-4-amine (13) N-(4-(4-aminophenyl-
sulfonyl) phenyl-7-(trifluoromethyl)quinolin-4-amine (14). – A mixture of 4,7-dichloroquinoline 
or 4-chloro-7-trifluoromethylquinoline (0.01 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 
mL) was refluxed for 24 h. The obtained solid was recrystallized from dioxane to give 13 
and 14, respectively (Table I).
N,N’-(4,4’-sulfonylbis(4,1-phenylene)bis(7-chloroquinolin-4-amine) (15), N,N’-(4,4’-
sulfonylbis(4,1-phenylene)bis(7-(trifluoromethyl)quinolin-4-amine) (16). – A mixture of 4,7-di-
chloroquinoline or 4-chloro-7-trifluoromethylquinoline (0.02 mol) and dapsone (2.28 g, 
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0.01 mol) in DMF (20 mL) was refluxed for 18 h. The obtained solid was recrystallized from 
ethanol to give 15 and 16, respectively (Table I).
7-Chloro-4-isothiocyanatoquinoline (17). – A mixture of 4,7-dichloroquinoline  (1.98 g, 
0.01 mol) and ammonium thiocyanate (1.52 g, 0.01 mol) in dry acetone (20 mL) was refluxed 
for 1 h. The reaction mixture was cooled, poured onto ice/water and the obtained solid was 
recrystallized from dioxane to give 17 (Table I). 
N-(4-(4-aminophenylsulfonyl) phenyl)-N-(7-chloroquinolin-4-yl)carbamimidothioic acid (18). 
– A mixture of 17 (2.20 g, 0.01 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) contain-
ing a catalytic amount of triethylamine was refluxed for 22 h. The obtained solid was re-
crystallized from acetic acid to give 18 (Table I). 
 N,N-(4,4’-sulfonylbis(4,1-phenylene)bis(N’-(7-chloroquinolin-4-yl)carbamimido-thioic acid 
(19). – A mixture of 17 (4.4 g, 0.02 mol) and dapsone (2.28 g, 0.01 mol) in DMF (20 mL) con-
taining 3 drops of triethylamine was refluxed for 24 h. The obtained solid was recrystal-
lized from dioxane to give 19 (Table I).
In vitro anti-proliferative activity
The cytotoxic activity in vitro of newly synthesized compounds was measured using the 
sulforhodamine B stain (SRB) assay and the method of Skehan (19). The human breast cancer 
cell lines MCF7 (obtained from National Cancer Institute, Cairo, Egypt) also were main-
tained at 37 °C in 5 % CO2 as subconfluent monolayers in 80 cm3 culture flasks (Nunclon) and 
were subcultured once or twice weekly in Dulbecco’s modification of Eagle’s medium (Flow) 
supplemented with 5 % heat-inactivated fetal calf serum (FCS) and 1 mmol L–1 L-glutamine. 
During experiments, 50 µg mL–1 gentamicin was added to the culture medium. Passage 
levels were in the range of 5–20 according to the original receipt. Cells were harvested from 
exponential phase cultures by trypsinisation, counted and plated in 96-well flat bottomed 
microtitre plates (Greiner Labortechnik, Germany) (100 µL cell suspension containing 104 
cells per well). Following plating and a 24-h recovery to allow cells to resume exponential 
growth, 100 µL culture medium or culture medium containing the drug was added to the 
wells. Test compounds were dissolved in DMSO as a 0.1 µmol  L–1 stock solution (the final 
concentration of DMSO in culture medium was less than 0.1 %) and diluted with phosphate 
buffered saline (PBS) to form 10 µmol  L–1 stock solutions. Different concentrations of each 
test compound (5, 12.5, 25 and 50 µmol  L–1) were added to the cell monolayer. Triplicate wells 
were prepared for each individual dose. Monolayer cells were incubated with the 
compound(s) for 48 h at 37 °C and in an atmosphere of 5 % CO2. Forty eight hours after drug 
addition, cells were fixed with 50 % trichloroacetic acid at 4 °C (50 µL/well) for 1 h, washed 
with 1 % acetic acid and stained for 30 min with 50 µL of 0.4 % (m/V) SRB dissolved in 1 % 
acetic acid. Excess unbound dye was removed by four washes with 1 % acetic acid and at-
tached stain was recovered with Tris-EDTA buffer. Colour intensity was measured using an 
enzyme-linked immunosorbent assay ELISA reader. Optical density was read at 510 nm. The 
relation between the surviving fraction and drug concentration was plotted to get the sur-
vival curve for the breast cancer cell line (MCF7) after specified time (19). The molar concen-
tration required for 50 % inhibition of cell viability (IC50) was preliminarily calculated from 
the constructed dose-response curve using Prism software (Graphpad, Inc., USA) and the 
results are given in Table III. 
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A new series of aminoquinoline derivatives 1–19 was prepared starting from 
4,7-dichloroquinoline or 4-chloro-7-trifluoromethylquinoline as depicted in Schemes 1-3. 
The synthesis of quinoline derivatives 1–12 is outlined in Scheme 1. Compounds 1 and 2 
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were obtained in good yields via the reaction of 4,7-dichloroquinoline or 4-chloro-7-triflu-
oromethylquinoline with 3,4,5-trimethoxyaniline and 1-adamantylamine in DMF, respec-
tively. IR spectrum of 1 revealed a characteristic band at 3390 cm–1 (NH). 1H NMR spec-
trum indicated the presence of signals at 3.8 ppm, which could be assigned to 3 OCH3 and 
a singlet at 9.5 ppm for the NH group. 1H NMR spectrum of compound 2 exhibited signals 
at 1.64, 1.76 and 2.14 ppm assigned to adamantane protons (Table II). On the other hand, 
when 4,7-dichloroquinoline and 4-chloro-7-trifluoromethylquinoline reacted with 4-ami-
nomorpholine, the corresponding 4-aminomorpholinophenyl derivatives 3 and 4 were 
obtained, respectively. IR spectra of compounds 3 and 4 showed the presence of characte-
ristic bands at 3189, 3360 cm–1 (NH). 1H NMR spectra of 3 and 4 indicated the presence of 
signals at 3.1 and 3.7 ppm for 4 CH2 of the morpholino moiety. Further, pyrimidine deri-
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vatives 5 and 6 were obtained in good yields via the reaction of 4-chloro-7-trifluorometh-
ylquinoline with 5-aminouracil and 6-amino-1,3-dimethyl uracil in refluxing DMF, respec-
tively. IR spectra exhibited the presence of an NH and 2 C=O groups. 1H NMR spectrum 
of 5 revealed a signal at 7.6 ppm assigned to the CH of uracil and others at 11.0 and 11.4 
ppm due to the 2 NHs of uracil. 1H NMR of 6 indicated the presence of 2 CH3 groups at 2.5 
and 3.3 ppm and CH uracil at 6.5 ppm (Table II). Interaction of 4,7-dichloroquinoline or 
4-chloro-7-trifluoromethylquinoline with pipronylamine gave the corresponding benzo[d]
[1,3]dioxol derivatives 7 and 8, respectively. 1H NMR spectra exhibited signals for CH2NH 
at 4.2 and 4.1 ppm and for OCH2O at 6.0 ppm. The 1,2,4-triazine derivative 9 was obtained 
through the reaction of 4-chloro-7-trifluoromethylquinoline with 3-amino-5,6-dimethyl-
1,2,4-triazine in DMF. 1H NMR spectrum showed signals at 2.3 ppm attributed to the 2 CH3 
groups and 8.8 ppm assigned to the NH group. Also, quinoline derivatives 10 and 11 were 
obtained via the reaction of 4-chloro-7-trifluoromethylquinoline with 3-aminoquinoline 
and 4-aminoquinaldine, respectively. 1H NMR spectrum of 10 revealed a singlet at 9.0 ppm 
for the NH group. 1H NMR spectrum of 11 showed a signal at 2.4 ppm for CH3 and another 
at 9.2 ppm for the NH group (Table II). Interaction of 4-chloro-7-trifluoromethylquinoline 
with 6-methoxybenzothiazole afforded the corresponding benzo[d] thiazole derivative 12. 
1H NMR spectrum indicated the presence of a triplet at 1.3 ppm for the CH3 group and a 
quartet at 4.0 ppm due to the CH2 group.
On the other hand, and as depicted in Scheme 2, when 4,7-dichloroquinoline or 
4-chlo ro-7-trifluoromethylquinoline reacted with dapsone in a molar ratio 1:1 in DMF, they 
afforded the corresponding 4-aminophenylsulfonyl derivatives 13 and 14, respectively, 
whereas conducting this reaction in a molar ratio 2:1, the corresponding bis-compounds 
15 and 16 were obtained in good yields. IR spectra of compounds 13 and 14 showed the 
presence of free NH2 bands at 6.2 ppm. 1H NMR spectra of 15 and 16 revealed signals at 
11.4 and 9.7 ppm for the 2 NH groups (Table II). 
Isothiocyanate derivative 17  was synthesized by treatment of compound 4,7-dichlo-
roquinoline with ammonium thiocyanate in dry acetone for 1 h (Scheme 3). This method 
led to higher overall yield and shorter working time in comparison with the reported 
method using silver thiocyanate (19). IR spectrum of 17 showed the characteristic band at 
2072 cm–1 assigned to N=C=S. Interaction of 17 with dapsone (1:1 mol) yielded the cor-
responding thiourea derivative 18, whereas conducting this reaction in molar ratio 2:1 af-
forded the corresponding bis-compound  19. Structures of compounds 18 and 19 were 
supported by elemental analysis and spectral data. IR spectrum of 18 revealed the pre-
sence of a band corresponding to free NH2, while IR spectrum of 19 showed bands at 3440 
and 3396 cm–1 for 2 NH groups. 1H NMR spectrum of compound 18 exhibited signals at 
2.6 ppm assigned to the SH group and 4.9 ppm attributed to the NH2 group. 1H NMR 
spectrum of compound 19 revealed signals at 2.7 ppm for the SH group and at 10.7 ppm 
due to 2 NH groups (Table II).
In vitro anti-proliferative activity and SAR
All the newly synthesized compounds were evaluated for their in vitro cytotoxic acti-
vity against the breast cancer cell line (MCF-7) compared with that of doxorubicin. The 
response parameter calculated was the IC50 value, which corresponds to the concentration 
required for 50 % inhibition of cell viability (Table III). The most active derivative in this 
study was the 3,4,5-trimethxyphenyl4-aminoquinoline derivative (1, IC50 = 9.38 µmol L–1) 
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Table II. Spectral data of the newly synthesized compounds
Compd. IR (nmax, cm–1) 1H NMR (DMSO-d6) (d, ppm) 13C NMR (DMSO-d6) (d, ppm)
1 3390 (NH), 3079  
(CH arom.), 2946, 
2836 (CH aliph.), 
1618 (C=N)
3.8 (s, 9H, 3OCH3), 7.0, 8.7 (2d, 2H, 2CH 
quinoline, J = 7.5 Hz), 7.1, 8.5 (m, 5H, Ar-H), 
9.5 (s, 1H, NH, D2O-exchangeable)
55.7 (2), 56.0, 99.6 (2), 121.0, 
122.7, 124.5, 124.6, 127.1, 129.7, 
130.4, 133.9, 135.0, 145.6, 149.6, 
151.1(2), 153.4
2 3296 (NH), 3079  
(CH arom.), 2970, 
2862 (CH aliph.), 
1621 (C=N)
1.64 (s, 6H, adamantane-H), 1.76 (s, 3H, 
adamantane-H), 2.14 (s, 6H, adamantane-
H), 4.2 (s,1H, NH, D2O-exchangeable), 
7.0, 8.6 (2d, 2H, 2CH quinoline,  J = 7.6 Hz), 
3.8 (s, 9H, 3OCH3), 7.0, 8.7 (2d, 2H, 2CH 
quinoline, J = 7.5 Hz), 7.6-8.4 ( m, 3H, Ar-H), 
9.8 (s, 1H, NH, D2O-exchangeable)
28.9, 35.6 (2), 38.9 (3), 40.3 (3), 
52.9, 119.1, 124.4, 124.7, 125.0, 
127.1, 129.7, 129.9, 145.5, 148.9, 
149.5  
3 3189 (NH), 3096  
(CH arom.), 2956, 
2838 (CH aliph.), 
1627 (C=N)
3.1 (s, 4H, N-CH2-N), 3.7 (s, 4H, O-CH2-O), 
6.8, 8.8 (2d, 2H, 2CH quinoline, J = 7.0 Hz), 
7.0-8.4 (m, 7H, Ar-H), 10.7 (s, 1H, NH, 
D2O-exchangeable)
48.0 (2), 66.0 (2), 112.3, 115.6 
(2), 116.0 (2), 120.5, 125.7, 
126.6, 128.2, 133.6, 137.4, 140.7, 
144.4, 149.9, 154.1
4 3360 (NH), 3100  
(CH arom.), 2973, 
2855 (CH aliph.), 
1610 (C=N)
3.1, 3.7 (2s, 8H, 4CH2), 6.7, 8.6 (2d, 2H, 2CH 
quinoline, J = 6.9 Hz), 7.0-8.4 (m, 7H, Ar-H), 
9.0 (s, 1H, NH, D2O-exchangeable)
48.0 (2), 66.0 (2), 115.9 (2), 
119.3, 120.0 (2), 121.2, 124.1, 
125.2, 126.4, 129.1, 129.4, 
130.9, 147.8, 148.5, 149.1, 152.2
5 3273, 3196 (NH), 




6.5, 8.5 (2d, 2H, 2CH quinoline, J = 7.8 Hz), 
7.6 (s, 1H, CH uracil), 7.7-8.4 (m, 4H, Ar-H), 
8.5 (s, 1H, NH, D2O-exchangeable), 11.0, 11.4 
(2s, 2H, 2NH uracil, D2O-exchangeable)
112.2, 119.0, 120.0, 123.0, 
124.0, 125.1, 128.8, 129.3, 
129.6, 147.3, 150.3, 151.0, 151.9, 
161.8
6 3391 (NH), 3086  
(CH arom.), 2961, 




2.5 (s, 3H, CH3), 6.5 (s, 1H, CH uracil), 
7.5, 8.7 (2d, 2H, 2CH quinoline, J = 8.1 Hz), 
7.7-8.6 (m, 3H, Ar-H), 9.1 (s, 1H, NH, 
D2O-exchangeable)
28.0, 29.6, 78.0, 114.6, 121.0, 
122.8, 123.1, 126.0, 128.8, 
136.7, 147.7, 149.4, 151.6, 152.1, 
161.8, 166.9
7 3278 (NH), 3068  
(CH arom.), 2946, 
2873 (CH aliph.), 
1612 (C=N), 755 
(C-Cl)
4.2 (s, 2H, CH2), 6.0 (s, 2H, O-CH2-O),
6.8, 8.8 (2d, 2H, 2CH quinoline, J = 7.4 Hz), 
7.0-8.0 (m, 6H, Ar-H), 9.0 (s, 1H, NH, 
D2O-exchangeable)
45.7, 103.7, 113.3, 116.7, 119.3, 
120.6, 122.1, 125.7, 129.6, 
130.6, 137.0 (2), 145.8, 146.9, 
149.3, 155.6, 157.3
8 3381 (NH), 3075 
(CH arom.), 2951, 
2836 (CH aliph.), 
1618 (C=N)
4.1 (s, 2H, CH2), 6.0 (s, 2H, O-CH2-O),  
6.8, 8.7 (2d, 2H, 2CH quinoline, J = 7.1 Hz), 
7.0-7.9 (m, 6H, Ar-H), 8.9 (s, 1H, NH, 
D2O-exchangeable)
47.8, 102.9, 113.7, 116.9, 117.6, 
121.7, 122.9, 124.0, 124.6, 126.7, 
130.6, 132.7, 135.0, 144.8, 
148.3, 149.1, 150.6, 153.9
9 3412 (NH), 3091 
(CH arom.), 2976, 
2866 (CH aliph.), 
1618 (C=N)
2.3 (s, 6H, 2CH3), 6.9, 8.6 (2d, 2H, 2CH 
quinoline, J = 7.7 Hz), 7.4-8.4 (m, 3H, Ar-H), 
8.8 (s, 1H, NH, D2O-exchangeable)
17.9 (2), 118.4, 124.4, 125.0, 
126.7, 127.2, 128.7, 129.2, 140.5, 
141.8, 146.2, 148.2, 151.8, 156.4 
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10 3360 (NH), 3056 
(CH arom.), 1621 
(C=N)
7.2, 8.7 (2d, 2H, 2CH quinoline, J = 7.7 Hz), 
7.5-8.4 (m, 9H, Ar-H), 9.0 (s, 1H, NH, 
D2O-exchangeable)
115.5, 120.3, 121.6, 122.8, 
124.5, 125.4, 126.8, 127.5, 
128.6, 129.8 (2), 130.3, 133.7, 
142.8, 144.6, 146.6, 147.4, 
148.2, 151.4
11 3291 (NH), 3066 
(CH arom.), 2976, 
2856 (CH aliph.), 
1620 (C=N)
2.4 (s, 3H, CH3), 6.4 (s, 1H, CH quinoline), 
6.5, 8.9 (2d, 2H, 2CH quinoline, J = 6.9 Hz), 
7.2-8.3 (m, 7H, Ar-H), 9.2 (s, 1H, NH, 
D2O-exchangeable)
24.7, 110.9, 117.2, 120.3, 122.5, 
122.9, 123.1, 124.6, 126.8, 
127.3, 128.0, 130.1, 130.6, 130.9, 
147.3, 148.4, 151.4, 152.2, 153.5, 
158.1
12 3312 (NH), 3086 
(CH arom.), 2961, 
2846 (CH aliph.), 
1612 (C=N)
1.3 (t, 3H, CH3), 4.0 (q, 2H, CH2), 6.7, 8.8 
(2d, 2H, 2CH quinoline, J = 7.0 Hz), 6.9-8.4 
(m, 6H, Ar-H), 10.8 (s, 1H, NH, D2O-
exchangeable)
14.6, 63.5, 105.5, 115.3, 118.0, 
120.7, 121.3, 122.8, 123.9, 125.0, 
126.7, 131.8, 132.8, 142.3, 148.2, 
151.9, 153.4, 155.4, 164.6
13 3361, 3348, 3215 
(NH, NH2), 3100 
(CH arom.), 1593 
(C=N), 1375, 1147 
(SO2), 748 (C-Cl)
6.2 (s, 2H, NH2, D2O-exchangeable), 
6.7, 8.8 (2d, 2H, 2CH quinoline, J = 7.4 Hz), 
7.1-8.3 (m, 11H, Ar-H), 10.8 (s, 1H, NH, D2O-
exchangeable)
112.9, 119.3 (4), 121.7, 123.3, 
127.2, 129.1 (4), 129.3, 135.3 (2), 
137.4, 146.3, 148.7, 149.4, 151.7, 
153.4
14 3417, 3365, 3310 
(NH, NH2), 3091 
(CH arom.), 1594 
(C=N), 1381, 1145 
(SO2)
6.2 (s, 2H, NH2, D2O-exchangeable), 
6.6, 8.8 (2d, 2H, 2CH quinoline, J = 6.8 Hz), 
7.3-8.3 (m, 11H, Ar-H), 10.7 (s, 1H, NH, 
D2O-exchangeable)
117.0, 119.3 (4), 121.9, 123.3, 
124.5, 125.8, 127.8, 128.9 (2), 
129.2 (2), 130.1, 130.5 (2), 
145.6, 147.8, 152.7, 153.5, 160.2
15 3421, 3267 (NH), 
3079 (CH arom.), 
1616 (C=N), 1361, 
1151 (SO2), 788 
(C-Cl)
7.1, 8.6 (2d, 2H, 2CH quinoline, J = 7.9 Hz), 
7.5-8.2 (m, 14H, Ar-H), 11.4 (s, 2H, 2NH, 
D2O-exchangeable)
116.6 (2), 119.6 (4), 124.0 (2), 
124.5 (2), 126.4 (2), 127.6 (4), 
129.2 (2), 138.4 (2), 139.5 (2), 
142.5 (2), 144.2 (2), 153.7 (2), 
162.2 (2)
16 3381, 3267 (NH), 
3055(CH arom.), 
1619 (C=N), 1372, 
1162 (SO2)
6.6, 8.6 (2d, 2H, 2CH quinoline, J = 7.5 Hz), 
7.3-8.5 (m, 14H, Ar-H), 9.7 (s, 2H, 2NH, 
D2O-exchangeable)
112.9 (2), 119.5 (4), 122.7 (2), 
123.0 (2), 124.7 (2), 126.3 (2), 
128.9 (2), 129.9 (4), 134.4 (4), 
146.3 (2), 147.7 (2), 149.6 (2), 
152.2 (2)
17 2072 (N=C=S) 
1616 (C=N), 879 
(C-Cl)
6.9, 8.9 (2d, 2H, 2CH quinoline, J = 6.8 Hz), 
7.2-8.4 (m, 3H, Ar-H)
118.8, 126.6, 127.7, 129.8, 130.6, 
136.4, 138.9, 140.4, 150.9, 152.0
18 3446, 3386, 3290 
(NH, NH2), 3081 
(CH arom.), 1595 
(C=N), 1381, 1182 
(SO2), 833 (C-Cl)
2.6 (s, 1H, SH, D2O-exchangeable), 
4.9 (br s, 2H, NH2, D2O-exchangeable), 
6.6, 8.6 (2d, 2H, 2CH quinoline, J = 6.9 Hz), 
7.0-8.4 (m, 7H, Ar-H), 10.8 (s, 1H, NH, 
D2O-exchangeable)
113.0, 119.2 (4), 125.0, 128.5, 
129.1 (5), 129.5, 137.4 (2), 139.0, 
147.8, 148.1, 152.5, 153.6, 160.2
19 3446, 3396 (NH), 
1596 (C=N), 1319, 
1145 (SO2)
2.7 (s, 2H, 2SH, D2O-exchangeable), 
6.6, 8.9 (2d, 4H, 4CH quinoline, J = 7.2 Hz), 
7.4-8.3 (m, 14H, Ar-H), 10.7 (s, 2H, 2NH, 
D2O-exchangeable)
115.8 (2), 119.1 (4), 124.8 (2), 
127.8 (2), 128.2 (6), 128.4 (2), 
129.1 (2), 142.1 (2), 144.7 (2), 
153.4 (2), 155.9 (2), 160.3 (2), 
162.3 (2)
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Table III. In vitro anti-proliferative screening of the newly synthesized compounds against the human breast 
cancer cell line (MCF-7)
Compd. 
Compound concentration (µmol L–1)
IC50
(µmol L–1)5 12.5 25 50
Surviving fractiona 
Doxo-
rubicin 0.551 ± 0.026 0.480 ± 0.003 0.139 ± 0.005 0.130 ± 0.016 32.00
1 0.512 ± 0.017 0.488 ± 0.015 0.442 ± 0.003 0.400 ± 0.027 9.38
2 0.801 ± 0.012 0.650 ± 0.041 0.485 ± 0.047 0.453 ± 0.022 24.10
3 0.873 ± 0.074 0.562 ± 0.033 0.523 ± 0.004 0.442 ± 0.021 31.50
4 0.746 ± 0.032 0.625 ± 0.024 0.481 ± 0.023 0.391 ± 0.015 23.30
5 0.835 ± 0.021 0.638 ± 0.058 0.442 ± 0.004 0.356 ± 0.016 21.40
6 0.775 ± 0.044 0.580 ± 0.012 0.489 ± 0.014 0.458 ± 0.065 23.30
7 0.692 ± 0.002 0.606 ± 0.009 0.450 ± 0.028 0.310 ± 0.047 21.10
8 0.895 ± 0.085 0.581 ± 0.016 0.508 ± 0.022 0.335 ± 0.043 26.20
9 0.861 ± 0.020 0.642 ± 0.020 0.452 ± 0.010 0.394 ± 0.030 21.80
10 0.686 ± 0.064 0.520 ± 0.014 0.358 ± 0.016 0.302 ± 0.012 14.20
11 0.630 ± 0.064 0.562 ± 0.014 0.345 ± 0.016 0.357 ± 0.012 16.30
12 0.777 ± 0.002 0.620 ± 0.009 0.591 ± 0.028 0.600 ± 0.047 NAb
13 0.764 ± 0.058 0.569 ± 0.026 0.436 ± 0.030 0.345 ± 0.022 18.80
14 0.669 ± 0.002 0.596 ± 0.009 0.487 ± 0.028 0.392 ± 0.047 23.50
15 0.857 ± 0.002 0.679 ± 0.009 0.474 ± 0.028 0.440 ± 0.047 23.20
16 0.827 ± 0.058 0.650 ± 0.026 0.487 ± 0.030 0.402 ± 0.240 24.00
17 0.853 ± 0.002 0.713 ± 0.009 0.447 ± 0.028 0.415 ± 0.047 22.40
18 0.895 ± 0.017 0.748 ± 0.015 0.444 ± 0.003 0.397 ± 0.027 22.70
19 0.564 ± 0.011 0.440 ± 0.010 0.142 ± 0.007 0.149 ± 0.013 33.60
a Mean ± SD, n = 3.
b NA – no activity observed under the adopted experimental conditions.
showing excellent anti-proliferative efficacy, being almost thrice as potent as doxorubicin 
(IC50 = 32.00 µmol L–1). Also, 3-quinolinyl derivatives (10, IC50 = 14.20 µmol L–1) and its 
2-methyl analogue (11, IC50 = 16.30 µmol L–1) displayed very high activity, being approxi-
mately double as potent as doxorubicin.
To investigate the effect of increasing lipophilicity on the biological activity of this 
class of compounds, the pyrimidine-2,4-dione derivative 5 and its 1,3-dimethyl analogue 
6 were prepared. Cytotoxic screening results showed that the more lipophilic derivative 
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6 with IC50 = 23.30 µmol L–1 was slightly less active than its dimethyl counterpart 5 with 
IC50 = 21.40 µmol L–1. Similar findings were observed for the quinoline-4-yl derivative 10 
and its 2-methylquinolin-4-yl isostere 11 displaying IC50 values of 14.20 and 16.30 µmol L–1, 
respectively. 
Regarding bis-compounds, there seemed to be no priority for preparing the bis-ana-
logues over their counterparts, since they did not demonstrate any enhancement of activ-
ity. Looking at the data for compounds 13 and 14 (IC50 values 18.80 and 23.50 µmol L–1, 
respectively) and their respective bis-compound derivatives 15 and 16 (IC50 values 23.20 
and 24.00 µmol L–1, respectively), a reduction in activity was observed. A more explicit 
example was evidenced by compound 18 and its bis-compound 19 eliciting IC50 values of 
22.70 and 33.60 µmol L–1, respectively. 
While seventeen out of nineteen synthesized compounds showed higher potency 
than doxorubicin, dapsone bis-compound (19) was almost as active as doxorubicin (IC50 of 
33.60 viz. 32.00 µmol L–1) and benzothiazole derivative (12) was not active in the adopted 
experimental procedure.
Finally, it is noteworthy that the cells killing potency of the 7-chloro derivatives was 
usually better than that of their 7-trifluoromethyl.  Thus, compound 7  having a chloro 
group at 7-position with IC50 value 21.10 µmol L–1 was more active than compound 8 bear-
ing trifluoromethyl moiety at the same position IC50 value 26.20 µmol L–1. Also, compound 
13 with IC50 of 18.80 µmol L–1 showed a significant cytotoxic activity, which was even 
higher than countercompound 14 with IC50  23.50 µmol L–1. In addition, bis-compound 15 
carrying a chloro group (IC50 value 23.20 µmol L–1) was found to possess higher potency 
than  bis-compound 16 incorporating trifluoromethyl moiety IC50 value 24.00 µmol L–1. The 
presence of the chloro group at position 7 in compounds 7, 13, 15 is supposed to enhance 
their anticancer activity. An exception was observed by the analogous pair 3 and 4 where 
7-chloro derivative 3 had lower potency (IC50 31.50 and 23.30 µM, respectively). It is clear 
from the present data that the comparison of the cytotoxicity of quinoline derivatives 
against the breast cancer cell line (MCF7) (Table III) has shown that the cell killing po-
tency follows the  order 1 > 10 > 11 > 13 > 7 > 5 > 9 > 17 > 18 > 15 > 4 > 6 > 14 > 16 > 2 > 8 > 3 > 
doxorubicin.  
CONCLUSIONS
The objective of the present study was to synthesize and investigate the anti-prolifer-
ative activity of some novel derivatives based on a 4-aminoquinoline backbone carrying 
variable biologically active moieties, viz., trimethoxyphenyl, adamantyl, pyrimidin-2,4-
dione, benzodioxole and dapsone, as well as a few bis-compounds. The anti-proliferative 
screening results of the new compounds against MCF-7 showed that seventeen com-
pounds were more potent than the reference drug doxorubicin. Among them, 7-(trifluo ro-
methyl)-N-(3,4,5-trimethoxyphenyl)quinolin-4-amine (1), N-(7-(trifluoromethyl)quinolin-
4-yl)quinolin-3-amine (10), 2-methyl-N-(7-trifluoromethyl)quinolin-4-yl)quinolin-3-amine 
(11) and N-(4-(4-aminophenylsulfonyl)phenyl)-7-chloroquinolin-4-amine (13). 1, 10 and 11 
were almost twice to thrice as potent as doxorubicin. We have inferred from the biological 
assessment data that this class of derivatives represents a very promising starting point 
for the design and synthesis of more analogues with further improved anti-proliferative 
activity. In vivo and toxicity studies of these compounds are under way.
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